Top Story Today
CytomX's Disguised Cancer Drug Stuns Wall Street, Then Loses a $1.6B Partner the Same Day
CytomX Therapeutics' stock rocketed approximately 56% after its "masked" antibody-drug conjugate posted a 32% response rate in late-line colorectal cancer patients, a population where almost nothing works. The drug, Varseta-M, circulates harmlessly through the body wearing a molecular disguise that only gets stripped away by enzymes found in tumors. In the same breath, CytomX revealed that Astellas had walked away from a $1.6 billion partnership on its T-cell engager programs. JPMorgan upgraded the stock.
Why it matters: The data validates CytomX's Probody masking platform in one of oncology's toughest settings, potentially opening up a colorectal cancer market that very few therapies have cracked, while proving that next-generation ADC engineering can meaningfully reduce off-target toxicity.
Read more →Clinical Wins and Pipeline Moves
Pfizer's Quiet Plan to Replace Its Own $14.6B Blockbuster Class
Pfizer's selective CDK4 inhibitor atirmociclib cut the risk of disease progression by 40% in a Phase 2 breast cancer trial, validating a next-gen approach that blocks tumor growth while sparing healthy blood cells. Unlike current CDK4/6 drugs (including Pfizer's own Ibrance), atirmociclib leaves CDK6 alone, potentially avoiding the anemia that plagues the existing class. A Phase 3 trial in the lucrative first-line setting is already underway.
Read more →Bayer's Kidney Drug Goes 5 for 5 in Phase III Trials
Kerendia (finerenone) just posted its fifth consecutive Phase III win, this time showing it significantly slowed kidney decline in non-diabetic CKD patients. That's a massive new population beyond the drug's existing diabetic CKD approval. With Bayer grinding through 12,000 layoffs and a painful restructuring, Kerendia's path to over 3 billion euros in peak sales just got a lot more credible.
Read more →Sarepta's $3.2M Gene Therapy Has a Liver Problem. Can a Second Drug Fix It?
After two patient deaths from liver failure, Sarepta is testing whether adding sirolimus (an immune-suppressing drug) to its Duchenne muscular dystrophy gene therapy Elevidys can prevent the toxicity that forced it to suspend treatment for non-ambulatory patients. The new trial cohort will enroll 25 patients, and the results could set a safety blueprint for the entire AAV gene therapy field.
Read more →Vertex Files for Approval of a Kidney Drug That Could Bring in $4B a Year
Vertex completed its FDA filing for povetacicept in IgA nephropathy, posting a 52% reduction in proteinuria from baseline in Phase 3. The filing marks Vertex's boldest diversification move beyond cystic fibrosis. It enters a crowded field (Otsuka and Novartis already have approved drugs), but povetacicept's dual BAFF/APRIL mechanism and once-monthly dosing could carve out meaningful share in a multi-billion-dollar market.
Read more →Deals, M&A, and Big Money Moves
Amplifon Drops 2.3 Billion Euros to Buy the Hearing Aids It Already Sells
The world's largest hearing care retailer (10,000+ stores across 25 countries) just agreed to acquire GN Hearing, the company that makes the ReSound and Beltone brands. The deal creates a vertically integrated giant in a market quietly booming thanks to aging demographics and AI-powered devices. Competitors who currently supply Amplifon's shelves just watched their biggest customer become their biggest rival.
Read more →Lilly and Roche Drop Nearly $1 Billion on South Korea in the Same Week
Eli Lilly committed $500 million and Roche pledged roughly $481 million to South Korea's biotech sector within six days of each other. Lilly is building an open innovation lab inside Samsung Biologics' campus; Roche is focused on clinical trials and talent development. The stampede reflects Korea's cost advantages, its booming $7.86 billion licensing deal market, and the BIOSECURE Act pushing supply chains away from China.
Read more →A New $78M Startup Thinks Kidney Patients Deserve Fewer Pills
R1 Therapeutics launched with an oversubscribed $77.5 million Series A to develop AP306, a drug that blocks phosphate absorption at the source instead of relying on the pill-heavy binder approach dialysis patients currently endure. DaVita's venture arm and U.S. Renal Care both invested, giving R1 direct access to the clinics where its future patients sit. A global Phase 2b trial kicks off later this year.
Read more →Regulatory and Corporate Shakeups
The FDA Just Made Copycat Biologics a Whole Lot Cheaper to Build
New draft guidance could cut biosimilar development costs by $20 million per product by letting companies skip expensive three-way clinical studies when they can prove, through lab analysis, that a foreign comparator matches the U.S. version. Stacked with October's guidance reducing efficacy trial requirements, the FDA is systematically lowering the barrier to entry in a $192 billion biologics market where many upcoming patent expirations have no biosimilar competition in sight.
Read more →Idorsia's CEO Lasted Nine Months. The Founder Is Back at the Wheel.
Idorsia's CEO departed by "mutual agreement," sending shares tumbling and forcing founder Jean-Paul Clozel back into the interim role. The Swiss biopharma is mid-turnaround, with losses narrowing and its insomnia drug QUVIVIQ doubling sales to CHF 134 million. But the leadership revolving door threatens to derail a plan that hinges on hitting overall profitability by the end of 2027.
Read more →